AMICUS THERAPEUTICS - Key Persons
Job Titles:
- Chief Operating Officer
- Member of the Science and Technology Committee
- President
Bradley L. Campbell is the President and Chief Operating Officer of Amicus Therapeutics and is also a member of the Board of Directors. He brings nearly 20 years of experience in the Orphan Drug industry. Mr. Campbell joined Amicus in 2006 and leads the global organization responsible for the commercialization of Galafold®. He also oversees the Technical Operations, Market Access, Program Management, Clinical Operations and Regulatory Affairs functions.
Mr. Campbell currently serves on the Board of the Association for Regenerative Medicine (ARM) and the Corporate Advisory Board for the National Tay-Sachs and Allied Diseases Association. He previously served on the Board of Progenics Pharmaceuticals from 2016 until its successful acquisition by Lantheus Holdings in 2020, and the Board of ARYA Sciences Acquisition Corp III, a healthcare focused Special Purpose Acquisition Vehicle formed by Perceptive Advisor.
Prior to Amicus, Mr. Campbell spent time in various commercial and business development roles at Genzyme and Bristol-Myers Squibb and as a strategy consultant for Marakon Associates. He received a B.A. in Public Policy from Duke University and an M.B.A. from Harvard Business School.
Job Titles:
- Director
- Member of the Audit and Compliance Committee
- Member of the Board
- Member of the Nominating and Governance Committee
- Chief Executive Officer of Colmar Holdings
- Independent Director / Audit and Compliance Committee
Mr. Whitman has served as a member of the Board since 2019. Mr. Whitman has served as Chief Executive Officer of Colmar Holdings, a private investment company since 2019. He also serves as a member of the Board of Directors of Omega Healthcare Investors; Board of Directors of the Marine Corps Heritage Foundation; Board of Trustees of The Lovett School; and the Reserve Forces Policy Board. Previously, he served as Chief Executive Officer, Health Management Associates (Fortune 500, sold); Chief Financial Officer, Triad Hospitals (Fortune 500, sold); President, Deerfield Healthcare (private, sold); Vice President, Almost Family; and Investment Banker with Morgan Stanley. Concurrently through 2018, he served as a reserve Major General and the senior reserve officer of the United States Marine Corps, capping 33 years of service which included active duty during 1985-88 and 2009-18 when he served with the Secretary of Defense, led multiple deployments, and was Commanding General of Marine Forces Reserve and the 4th Marine Division. For civil society, Mr. Whitman previously served on the Boards of the Federation of American Hospitals, Toys for Tots Foundation, Marine Corps University, and on the Founders Group of the National Museum of the Marine Corps.
He holds an M.B.A. from Harvard Business School, a Master of Strategic Studies from Army War College, and a B.A. from Dartmouth College.
Mr. Whitman serves as member of the Nominating and Governance Committee and as member of the Audit and Compliance Committee.
Job Titles:
- Director
- Independent Director
- Member of the Nominating and Governance Committee
- Chairman of the Science and Technology Committee
- Chief Executive Officer of Headwaters Biotech Advisors
- Member of Our Board
Craig A. Wheeler has served as a member of our Board since June 2016. Mr. Wheeler is the Chief Executive Officer of Headwaters Biotech Advisors, where he serves as an advisor to executives in the Biotech industry. Previously, Mr. Wheeler was President and Chief Executive Officer of Momenta Pharmaceuticals, Inc., where he also served on the Board of Directors. He led Momenta through the launch of its first complex drug products, including the first generic versions of LOVENOX® and once-daily COPAXONE®. Prior to Momenta, Craig worked at Chiron Corporation as President, Chiron BioPharmaceuticals (now Novartis Vaccines ↦ Diagnostics). Prior to joining Chiron, Craig was a senior member of The Boston Consulting Group's health care practice and worked extensively in the health care sector with focus on pharma and biotech, particularly in regard to corporate and R&D strategy. Mr. Wheeler began his career at Merck & Company Inc. in the MSDRL research unit, where he served as a senior engineer in process development and at Hybritech as a financial analyst. Mr. Wheeler previously served for nine years as the Chairman of the Board of Avanir Pharmaceuticals where he helped oversee the transition of the company from a research-based platform to a fully integrated CNS pharmaceutical company until 2015 when it was acquired by Otsuka Pharmaceuticals for $3.5 billion. He also served as GPhA's Chairman of the Board of Directors from 2014 to February 2016.
He holds a B.S. and an M.S. degree in chemical engineering from Cornell University, and an M.B.A. from the Wharton School of the University of Pennsylvania.
Mr. Wheeler serves as chair of the Science and Technology Committee and as member of the Compensation and Leadership Development Committee.
Job Titles:
- Chief People Officer
- Leader
- Vice President of Global Human Resources at Alibaba Group in Hangzhou
David Clark is the Chief People Officer at Amicus Therapeutics. David has been a leader in human resources and talent development for more than two decades. His expertise is in leadership development, performance management, driving business results and large-scale complex change.
David joined Amicus in October 2018 after two years as Vice President of Global Human Resources at Alibaba Group in Hangzhou, China. Prior to that, David spent eight years at American Express, where he was Senior Vice President of HR and Chief Learning Officer. While there, David was a senior HR Business Partner and led the transformation of learning and leadership development and performance management.
Previously, David was a Commissioned Officer on the White House senior staff. As Deputy Assistant to the President of the United States, he led the recruitment and development of the 4,000 most senior leaders in the U.S. government.
David received a B.S. in political science from Indiana State University. He is an Eagle Scout and serves on the National Executive Board of the Boy Scouts of America (BSA). David is also the Chairman of the Board of the Make-A-Wish Foundation of America.
Dr. Jill Weimer joined Amicus in June 2019 and currently serves as the Chief Science Officer. She is a developmental neuroscientist by training and began her academic research program at Sanford Research and the University of South Dakota in 2009 as Assistant Scientist/Assistant Professor before entering her current position as Scientist/Professor. In addition to her role at Amicus, Dr. Weimer holds a leadership position at Sanford Research where she has served as Senior Director of Therapeutic Development since 2016. The work in Dr. Weimer's lab led to the first ever gene therapy trial programs for CLN3 and CLN6 Batten disease, programs that are both now being developed by Amicus. Dr. Weimer received a B.S. and Ph.D. in neuroscience from the University of Rochester, and completed her postdoctoral training in the Neuroscience Research Center at the University of North Carolina in Chapel Hill with a focus on developmental neuroscience. Dr. Weimer also serves as a scientific advisor to a number of rare disease foundations in addition to serving as the President of the Alumni Council for the University of Rochester School of Medicine and Dentistry.
Job Titles:
- Director
- Independent Director
- Member of the Audit and Compliance Committee
- Member of the Compensation
Eiry W. Roberts, M.D., has served as a member of our Board since 2021. Dr. Roberts is a former senior executive of Eli Lilly and Company and is currently the Chief Medical Officer of Neurocrine Biosciences, Inc. She has over 25 years of pharmaceutical drug development experience, ranging across all phases of development from research through commercialization, spanning multiple therapeutic areas. Prior to Neurocrine, Roberts spent 26-years at Eli Lilly, during which she advanced through various senior and executive level roles, concluding her tenure as Vice President in Research & Development. Roberts served as the Chair of the Medical Review Committee at Eli Lilly. She is a member of the Healthcare Business Women's Association and an Adjunct Professor of Medicine at Indiana University, Department of Clinical Pharmacology. She formerly served on the Springboard Ventures Steering Committee and was a member of the Indiana Health Forum. She has non-profit Board experience, previously serving on the Board of the Indianapolis Children's Choir and the St. Richard's Episcopal School Board of Trustees.
Dr. Roberts is an M.D. trained in pharmacology and medicine in the United Kingdom, qualifying from the University of London. Dr. Roberts continued her post-graduate clinical training in clinical pharmacology and cardiology at St. Bartholomew's Hospital and at the Royal London Hospital.
Ms. Roberts serves as member of the Compensation and Leadership Development Committee and as member of the Science and Technology Committee.
Ellen S. Rosenberg joined Amicus Therapeutics in February of 2016 and currently serves as Chief Legal Officer. She brings legal experience in the biopharmaceutical and medical device industry including mergers and acquisitions, product launches, risk management, and compliance matters. Prior to joining Amicus, she served as Senior Vice President, Associate General Counsel of Shire Pharmaceuticals. Prior to Shire, Ms. Rosenberg was Associate General Counsel for the Metabolic Endocrinology division at EMD Serono Inc., the U.S. affiliate of Merck KGaA.
Ms. Rosenberg received a B.A. from the University of Connecticut and a J.D. from the University of Pennsylvania Law School
Job Titles:
- Director
- Member of the Nominating and Governance Committee
- Independent Director / Audit and Compliance Committee
Job Titles:
- Chief Development Officer
Dr. Castelli joined Amicus in July 2005 and currently serves as Chief Development Officer. He has over 20 years of experience in the Biotech and Orphan Drug industry, focused on rare disease research and development of medicines from discovery through market authorization. In his current capacity, he provides strategic leadership across all R&D activities, including direct oversight of Science, Clinical Research, and Medical Affairs. Previously at Amicus he has had responsibility for a number of different functions including program management, portfolio planning and the gene therapy business. Prior to joining Amicus, Dr. Castelli was a healthcare strategy consultant at Health Advances LLC and worked in business development at Neose Pharmaceuticals Inc. He received a B.S. from West Chester University and a Ph.D. from the University of Pennsylvania, and is an author on numerous publications and patents in the field of rare disease drug development.
Job Titles:
- Chairman
- Chairman of the Board
- Chief Executive Officer
- Member of the Science and Technology Committee
John F. Crowley is our Chairman and CEO. John's involvement with biotechnology stems from the 1998 diagnosis of two of his children with Pompe disease-a severe and often fatal neuromuscular disorder. In his drive to find a cure for them, he left his position at Bristol-Myers Squibb and became an entrepreneur as the Co-founder, President and CEO of Novazyme Pharmaceuticals, a biotech start-up conducting research on a new experimental treatment for Pompe disease (which he credits as ultimately saving his children's lives). In 2001, Novazyme was acquired by Genzyme Corporation and John continued to play a lead role in the development of a drug for Pompe disease as Senior Vice President, Genzyme Therapeutics.
John and his family have been profiled on the front page of The Wall Street Journal and are the subjects of a book by Pulitzer prize-winning journalist Geeta Anand, "The Cure: How a Father Raised $100 Million-And Bucked the Medical Establishment-In a Quest to Save His Children." The major motion picture, Extraordinary Measures, starring Brendan Fraser and Harrison Ford, is inspired by the Crowley family journey. John is the author of a personal memoir: Chasing Miracles: The Crowley Family Journey of Strength, Hope, and Joy.
John served as a commissioned officer in the U.S. Navy Reserve, assigned to the United States Special Operations Command, and is a veteran of the global war on terrorism, with service in Afghanistan. He graduated with a B.S. in Foreign Service from Georgetown University, and earned a J.D. from the University of Notre Dame Law School and an M.B.A. from Harvard. The Crowley family was the recipient of the 2011 Family Exemplar Award from the University of Notre Dame. He is also a member of the University Council on Science & Technology at Notre Dame and the Wall Street Journal CEO Council. Currently, John serves as a member of the Board of Directors of Intellia Therapeutics, Inc. and Entrada Therapeutics, Inc. He is the former National Chairman of the Make-A-Wish Foundation of America and is a founding Board member of the Global Genes Project. John is a Henry Crown Fellow at the Aspen Institute.
Julie Yu first joined Amicus in January 2008 and currently serves as Chief Program Officer. She brings over 15 years of experience in the drug development industry, focused on program management and clinical operations. After joining Amicus in 2008, she took on increasingly senior roles including overseeing the Galafold® registrational studies. In her current capacity, Dr. Yu provides operational oversight across all development activities, including direct responsibility for Clinical Operations, Regulatory Affairs and Program Management. Prior to joining Amicus, Dr. Yu worked in project management at Merck & Co. Inc., and Biovail, and also previously worked in drug discovery and bioinformatics.
Dr. Yu received a B.Sc. in Immunology and an M.Sc. in Cardiovascular Pathology from the University of Toronto, Canada, a Ph.D. in Clinical Pharmacology from Cambridge University, UK, and an MBA focusing on Strategy, Change Management and Leadership from NYU Langone School of Business. She has been certified as a Project Management Professional since 2005.
Job Titles:
- Director
- Independent Director
- Member of the Audit and Compliance Committee
Job Titles:
- Director
- Independent Director
- Member of the Audit and Compliance Committee
- Chairman of the Compensation
- Member of Our Board
Margaret G. McGlynn has served as a member of our Board since October 2009. She retired from Merck after 26 years including roles as President of Global Vaccines and Infectious Disease and President, U.S. Hospital and Specialty Products. She also served in a variety of executive leadership roles in global and U.S. marketing, sales and managed care. Following her retirement from Merck, Ms. McGlynn served as CEO and President of The International AIDS Vaccine Initiative. Currently, Ms. McGlynn serves as a member of the Board of Directors of Vertex Pharmaceuticals, Inc. and of Novavax, Inc. She also serves on the Board of Buffalo BioNet Advisory Group (private) and the Board of the Advisory Committee, UB School of Pharmacy (private). Previously, she served on the Boards of Air Products and Chemicals, Inc. and Orphan Technologies. She is also Chair of the Board of HCU Network America, a non‑profit which provides advocacy and support research for patients affected by the rare disease homocystinuria. Ms. McGlynn holds a B.S. in Pharmacy and a MBA in Marketing from the State University of New York at Buffalo.
Ms. McGlynn serves as chair of the Compensation and Leadership Development Committee and as member of the Nominating and Governance Committee.
Job Titles:
- Director
- Member of the Audit and Compliance Committee
- Member of the Board
- Independent Director / Audit and Compliance Committee
Michael A. Kelly has served as a member of the Board since December 2020. Mr. Kelly is a former senior executive of Amgen, Inc. and is currently acting as Founder & President of Sentry Hill Partners, LLC, a global life sciences transformation and management consulting business founded by Mr. Kelly in 2018. Mr. Kelly has more than two decades of executive experience as a senior leader in the life sciences industry serving in various strategic finance and operations positions at Amgen Inc., most recently as Senior Vice President, Global Business Services and Vice President & CFO, International Commercial Operations. Mr. Kelly has also held positions at Biogen, Tanox, and Monsanto Life Sciences. Mr. Kelly is an independent member of the Board of Directors for publicly traded Aprea Therapeutics, DMC Global, Inc., NeoGenomics, Inc., and Hookipa Pharma, Inc. He also serves on the Council of Advisors and was the former audit committee chairman for Direct Relief, a humanitarian aid organization focused on health outcomes and disaster relief. Mr. Kelly holds a BSc in business administration from Florida A&M University, concentrating in Finance and Industrial Relations.
Mr. Kelly serves as member of the Audit and Compliance Committee and as member of the Science and Technology Committee.
Job Titles:
- Director
- Member of the Audit and Compliance Committee
- Independent Director / Audit and Compliance Committee
- Member of Our Board
Mike Raab has served as a member of our Board since 2004 and as Lead Independent Director since September 2018. Mr. Raab has served as President and Chief Executive Officer of Ardelyx, Inc. since March 2009. Mr. Raab previously served as a partner of New Enterprise Associates from June 2002 until December 2008. From 1999 to 2002, he was Senior Vice President, Therapeutics and General Manager, Renagel® at Genzyme Corporation. Mr. Raab currently serves as a member of the Board of Directors of Ardelyx, Inc and Millendo Therapeutics, Inc. He is the Chairman of Tempest Therapeutics, a clinical stage biotechnology company advancing small molecule therapeutics that modulate anti-tumor pathways. He also serves on the Emerging Companies and Health Section Governing Boards of the Biotechnology Innovation Organization.
Mr. Raab holds a B.A. from DePauw University.
Mr. Raab serves as Lead Independent Director, as chair of the Nominating and Governance Committee and as member of the Audit and Compliance Committee.
Job Titles:
- Senior Vice President, Global Chief Compliance & Risk Officer
Patrik Florencio is Senior Vice President, Global Chief Compliance & Risk Officer at Amicus Therapeutics. At Amicus, Mr. Florencio leads the Risk Management Department, which encompasses Corporate Compliance, ERM, Privacy, Quality Assurance, and Quality Control. Prior to Amicus, Mr. Florencio held a number of CCO positions, including Global Chief Compliance Officer of NPS Pharmaceuticals Inc. and Chief Corporate Compliance Officer, NA of Sandoz Inc. Mr. Florencio has also practiced health law at the law firm of Ropes & Gray in New York City, where he counseled pharmaceutical, hospital system, academic medical center, and other healthcare clients on a host of government enforcement, compliance, and regulatory matters. Mr. Florencio graduated with degrees in common law, civil law, and neuroscience from McGill University in Montreal, Canada.
Job Titles:
- Director
- Member of the Board
- Member of the Science and Technology Committee
- Independent Director / Audit and Compliance Committee
Robert Essner has served as a member of the Board since June 2012. He also serves as a member of the Board of Directors of Organon & Co. Mr. Essner retired as Chairman and Chief Executive Officer of Wyeth Pharmaceuticals, Inc., now part of Pfizer Inc., in 2008. During his 32‑year career in the pharmaceutical industry, he held several prominent leadership positions, including Chairman of the Pharmaceutical Research and Manufacturers Association. Prior to Wyeth, Mr. Essner spent more than a decade in various management positions at Sandoz Pharmaceuticals Corporation and as President of Sandoz Consumer Healthcare Group. Mr. Essner was formerly a Director at MassMutual Financial Group. Mr. Essner is also an Executive-in-Residence and Adjunct Professor at Columbia Business School, where he teaches courses in healthcare management. He received a Bachelor's degree from Miami University and a Master's degree from the University of Chicago.
Mr. Essner serves as member of the Audit and Compliance Committee.
Sébastien Martel joined Amicus in May 2021 and currently serves as Chief Business Officer. He brings 25 years of diversified pharmaceutical and biotechnology expertise to Amicus, with extensive experience in rare disease. In his current capacity, Mr. Martel leads the Corporate Strategy, Business Development, Alliance Management, Strategic Planning, and Corporate Communications functions. Prior to joining Amicus, Mr. Martel spent 12 years at Sanofi, most recently serving as Senior Vice President and Global Head of Rare Diseases, where he led the global rare disease business through multiple global product launches, commercialization, and disease awareness initiatives, in addition to guiding business development and portfolio strategy. Mr. Martel received a Doctor of Pharmacy Degree (PharmD) from the University of Angers, Faculty of Pharmacy, and an M.B.A. from the INSEAD Business School. He also holds a Masters in Management for the Pharmaceutical Industry from the Burgundy School of Business.